{"id":"safinamide-methanesulfonate","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Dyskinesia"},{"rate":"5-10","effect":"Fall"},{"rate":"2-5","effect":"Impulse control disorder"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL396778","moleculeType":"Small molecule","molecularWeight":"302.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting MAO-B, safinamide prevents the degradation of dopamine in the striatum, thereby increasing dopamine availability and enhancing motor function in Parkinson's disease patients. Additionally, safinamide has sodium channel blocking properties and may provide neuroprotective effects through modulation of glutamate release.","oneSentence":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain by blocking the enzyme responsible for dopamine breakdown.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:27.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease as adjunctive therapy to levodopa in patients with motor fluctuations"}]},"trialDetails":[{"nctId":"NCT03968744","phase":"PHASE4","title":"Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease","status":"TERMINATED","sponsor":"Alain Kaelin","startDate":"2019-02-18","conditions":"Idiopathic Parkinson's Disease (at Later Stage)","enrollment":11},{"nctId":"NCT07257393","phase":"","title":"Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2025-12-01","conditions":"Idiopathic Parkinsonism","enrollment":100},{"nctId":"NCT05312632","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2022-04-05","conditions":"Parkinson Disease","enrollment":201},{"nctId":"NCT03994328","phase":"","title":"An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-12-03","conditions":"Parkinson's Disease","enrollment":1235},{"nctId":"NCT03843944","phase":"PHASE4","title":"Overnight Switch From Rasagiline To Safinamide","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2018-05-01","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT03881371","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-08-01","conditions":"Parkinson Disease","enrollment":307},{"nctId":"NCT03944785","phase":"","title":"Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Idiopathic Parkinson Disease","enrollment":164},{"nctId":"NCT03841604","phase":"PHASE4","title":"Effect of Safinamide on Parkinson's Disease Related Chronic Pain","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-04-09","conditions":"Idiopathic Parkinson Disease","enrollment":94},{"nctId":"NCT03887221","phase":"PHASE1","title":"A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2021-06-21","conditions":"Healthy","enrollment":24},{"nctId":"NCT03753763","phase":"PHASE2","title":"Safinamide for Multiple System Atrophy (MSA)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-10-29","conditions":"Multiple System Atrophy","enrollment":49},{"nctId":"NCT03987750","phase":"PHASE3","title":"Safinamide for Levodopa-induced Dyskinesia (PD-LID)","status":"WITHDRAWN","sponsor":"Zambon SpA","startDate":"2019-10","conditions":"Dyskinesia, Drug-Induced, Parkinson Disease","enrollment":""},{"nctId":"NCT03648671","phase":"","title":"Pain in Parkinson's Disease With Motor Fluctuations.","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2018-03-28","conditions":"Parkinson Disease","enrollment":48},{"nctId":"NCT00865579","phase":"PHASE3","title":"Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients","status":"TERMINATED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":964},{"nctId":"NCT01264861","phase":"PHASE2","title":"A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging","status":"TERMINATED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2011-03","conditions":"Parkinson Disease","enrollment":5},{"nctId":"NCT03216304","phase":"PHASE1","title":"Safinamide Steady State Interaction With Rosuvastatin","status":"COMPLETED","sponsor":"Cross Research S.A.","startDate":"2017-05-22","conditions":"Healthy","enrollment":24},{"nctId":"NCT02495831","phase":"PHASE1","title":"Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2015-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT01028586","phase":"PHASE3","title":"MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)","status":"TERMINATED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-10","conditions":"Idiopathic Parkinson's Disease","enrollment":507},{"nctId":"NCT01113320","phase":"PHASE2","title":"Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2010-04","conditions":"Parkinson's Disease","enrollment":26},{"nctId":"NCT00627640","phase":"PHASE3","title":"Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-02","conditions":"Idiopathic Parkinson's Disease","enrollment":549},{"nctId":"NCT01211587","phase":"PHASE2","title":"A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2010-09","conditions":"Parkinson's Disease With Cognitive Impairments","enrollment":103},{"nctId":"NCT01374113","phase":"PHASE1","title":"Safinamide Renal Impairment Trial","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2011-06","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT01027169","phase":"PHASE1","title":"A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-04","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT01026428","phase":"PHASE1, PHASE2","title":"A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-09","conditions":"Idiopathic Parkinson's Disease","enrollment":24},{"nctId":"NCT01286935","phase":"PHASE3","title":"18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-08","conditions":"Parkinson's Disease","enrollment":544},{"nctId":"NCT01187966","phase":"PHASE3","title":"Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-01","conditions":"Parkinson's Disease","enrollment":669},{"nctId":"NCT00643045","phase":"PHASE3","title":"Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2004-12","conditions":"Idiopathic Parkinson's Disease","enrollment":269},{"nctId":"NCT00642889","phase":"PHASE3","title":"Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2005-06","conditions":"Parkinson's Disease","enrollment":227}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xadago"],"phase":"marketed","status":"active","brandName":"Safinamide Methanesulfonate","genericName":"Safinamide Methanesulfonate","companyName":"Zambon SpA","companyId":"zambon-spa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Safinamide is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain by blocking the enzyme responsible for dopamine breakdown. Used for Parkinson's disease as adjunctive therapy to levodopa in patients with motor fluctuations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}